Cargando…
FH535 inhibited metastasis and growth of pancreatic cancer cells
FH535 is a small-molecule inhibitor of the Wnt/β-catenin signaling pathway, which a substantial body of evidence has proven is activated in various cancers, including pancreatic cancer. Activation of the Wnt/β-catenin pathway plays an important role in tumor progression and metastasis. We investigat...
Autores principales: | Wu, Meng-Yao, Liang, Rong-Rui, Chen, Kai, Shen, Meng, Tian, Ya-Li, Li, Dao-Ming, Duan, Wei-Ming, Gui, Qi, Gong, Fei-Ran, Lian, Lian, Li, Wei, Tao, Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500609/ https://www.ncbi.nlm.nih.gov/pubmed/26185454 http://dx.doi.org/10.2147/OTT.S82718 |
Ejemplares similares
-
FH535, a β-catenin pathway inhibitor, represses pancreatic cancer xenograft growth and angiogenesis
por: Liu, Lu, et al.
Publicado: (2016) -
FH535 Inhibited Migration and Growth of Breast Cancer Cells
por: Iida, Joji, et al.
Publicado: (2012) -
FH535 increases the radiosensitivity and reverses epithelial-to-mesenchymal transition of radioresistant esophageal cancer cell line KYSE-150R
por: Su, Huafang, et al.
Publicado: (2015) -
FH535 Suppresses Osteosarcoma Growth In Vitro and Inhibits Wnt Signaling through Tankyrases
por: Gustafson, Carl T., et al.
Publicado: (2017) -
Downregulation of CSN6 attenuates papillary thyroid carcinoma progression by reducing Wnt/β‐catenin signaling and sensitizes cancer cells to FH535 therapy
por: Wen, Duo, et al.
Publicado: (2018)